Pharmafile Logo
Pharmafocus logo
Advanced Search

Sanofi

Showing 15 posts of 561 posts found.

testalize-me-0je8ynv4mis-unsplash

Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment

June 5, 2024
Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma

Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …

News

Sanofi, Formation Bio and OpenAI enter AI collaboration

May 22, 2024
Research and Development Formation Bio, OpenAI, Pharmacy, Sanofi, collaboration

Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with the aim of building AI-powered …

News

Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment

May 14, 2024
Research and Development Musculo-skeletal disorder, Sanofi, collaboration, fulcrum therapeutics, muscular dystrophy

Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with Sanofi for the development and …

News

Sanofi adds €1bn funding for biomanufacturing projects in France

May 13, 2024
Business Services Biomanufacturing, Pharmacy, Sanofi, funding, investment

Sanofi has announced that it has made a new investment of at least €1bn for the creation of new bioproduction …

News
Vaccine image

Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines

May 10, 2024
Sales and Marketing COVID-19, COVID-19 vaccine, Immunology, Novatex, Sanofi, flu-COVID-19 vaccine, licensing agreement

French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive licensing agreement for a number …

News

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024
Research and Development Cardiology, Sanofi, clinical trial, thrombocytopenia

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib 400mg twice daily oral treatment …

News

Sanofi shares phase 2b results for dermatitis treatment

March 12, 2024
Research and Development Dermatology, Sanofi, amlitelimab, atopic dermatitis, clinical trial, dermatitis

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study of amlitelimab for adult patients …

News

Sanofi to acquire Inhibrx for approximately $1.7bn

January 23, 2024
Business Services Inhibrx, Rare Diseases, Sanofi, acquisition

Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following …

News

AstraZeneca and Sanofi’s Beyfortus approved in China

January 2, 2024
Research and Development AstraZeneca, Beyfortus, China, Immunology, Sanofi

AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus …

News

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023
Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …

News

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

October 6, 2023
Research and Development Nexviazyme, Pharmacy, Pompe disease, Sanofi

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at …

News

Janssen and Sanofi enter agreement for potential vaccine programme

October 5, 2023
Business Services Immunology, Janssen, Sanofi, e coli, vaccines

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with Sanofi for Janssen’s extraintestinal pathogenic …

News
louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

October 4, 2023
Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …

News

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023
Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi

Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has accepted their supplemental Biologics License …

News

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023
Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …

News

Latest content

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024

Takeda shares data from phase 3 trial of CIPD treatment

June 20, 2024

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024

First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment

June 19, 2024

FDA approves Merck’s Capvaxive for prevention of pneumococcal disease

June 18, 2024